Global Information
회사소개 | 문의

중국의 엔테카비르(Entecavir) 시장 분석

Investigation Report on China Entecavir 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 11월 상품 코드 333477
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,516,500 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,774,800 Printable & Editable PDF (Enterprisewide License)


중국의 엔테카비르(Entecavir) 시장 분석 Investigation Report on China Entecavir 2018-2022
발행일 : 2018년 11월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

중국의 엔테카비르(Entecavir) 시장을 분석했으며, 시장의 기본 구조와 배경, 전체적인 시장 규모와 국내 가격 동향, 제형별 동향, 주요 제조업체 개요와 시장 점유율, 향후 시장 동향 전망 등을 조사했습니다.

제1장 엔테카비르의 관련 개념

  • 엔테카비르의 효능
  • 중국의 엔테카비르 개발 현황
  • 중국에서의 엔테카비르 정부 인증 상황

제2장 중국의 엔테카비르 판매 동향(과거 5년간)

  • 엔테카비르 판매액
    • 중국의 전체 판매액
    • 지역별 판매액
  • 엔테카비르 판매량
    • 중국의 전체 판매량
    • 지역별 판매량
  • 엔테카비르 판매량 : 제형별(과거 5년간)
    • 캡슐
    • 태블릿

제3장 중국의 엔테카비르 주요 제조업체 분석

  • 주요 제조업체별 시장 점유율(금액 및 수량 기준, 과거 5년간)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 기업 개요
    • 중국의 엔테카비르 매출액
  • Sino-American Shanghai Squibb Pharmaceuticals Ltd.
  • Jiangxi Qingfeng Pharmaceutical Co., Ltd.
  • Suzhou Dawnrays Pharmaceutical Co., Ltd.
  • Fujian Cosunter Pharmaceutical Co., Ltd.

제4장 중국의 엔테카비르 가격 동향

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.(Runzhong)
  • Sino-American Shanghai Squibb Pharmaceuticals Ltd.(Baraclude)
  • Jiangxi Qingfeng Pharmaceutical Co., Ltd.(Weiliqing)
  • Suzhou Dawnrays Pharmaceutical Co., Ltd.(Leiyide)
  • Fujian Cosunter Pharmaceutical Co., Ltd.(Enganding)

제5장 중국의 엔테카비르 시장 전망(향후 5년간)

  • 시장 규모 예측
  • 시장 동향 예측
LSH 18.11.08

The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.

Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI's market survey, the annual sales value of entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.

Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug's entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.

Topics covered:

  • market size of entecavir in China
  • competitive landscape of entecavir in Chinese market
  • price of entecavir made by different manufacturers in China
  • market outlook of entecavir in China

Table of Contents

1 Related Concepts of Entecavir

  • 1.1 Indications for Entecavir
  • 1.2 Development History of Entecavir in China
  • 1.3 Governmental Approval for Entecavir in China

2 Survey on Sales Status of Entecavir in China, 2013-2017

  • 2.1 Sales Value of Entecavir
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Entecavir
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Entecavir by Dosage Form in China, 2013-2017
    • 2.3.1 Capsules
    • 2.3.2 Tablets

3 Major Manufacturers of Entecavir in China, 2013-2017

  • 3.1 Market Share of Major Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China
  • 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China
  • 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China
  • 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China
  • 3.6 Fujian Cosunter Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China

4 Prices of Entecavir in China, 2017-2018

  • 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)
  • 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)
  • 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)
  • 4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide)
  • 4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding)

5 Market Outlook of Entecavir in China, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Government Approval for Entecavir Dispersible Tablets in China by Sept. 2018
  • Chart Sales Volume of Entecavir in China, 2013-2017
  • Chart Sales Value of Entecavir in Parts of China, 2013-2017
  • Chart Sales Volume of Entecavir in China, 2013-2017
  • Chart Sales Volume of Entecavir in Parts of China, 2013-2017
  • Chart Sales Value of Entecavir Capsules in China, 2013-2017
  • Chart Sales Volume of Entecavir Capsules in China, 2013-2017
  • Chart Sales Volume of Entecavir Tablets in China, 2013-2017
  • Chart Sales Volume of Entecavir Tablets in China, 2013-2017
  • Chart Market Share of Top 5 Entecavir Manufacturers by Sales Value, 2013-2017
  • Chart Market Share of Top 5 Entecavir Manufacturers by Sales Volume, 2013-2017
  • Chart Profile of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Chart Sales Value of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Volume of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
  • Chart Profile of Sino-American Shanghai Squibb Pharmaceuticals Ltd.
  • Chart Sales Value of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir, 2013-2017
  • Chart Sales Volume of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir, 2013-2017
  • Chart Profile of Jiangxi Qingfeng Pharmaceutical Co., Ltd.
  • Chart Sales Value of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Volume of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Profile of Suzhou Dawnrays Pharmaceutical Co., Ltd.
  • Chart Sales Value of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Volume of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Profile of Fujian Cosunter Pharmaceutical Co., Ltd.
  • Chart Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in Parts of China in 2017
  • Chart Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in Parts of China in 2017
  • Chart Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir (Weiliqing) in Parts of China in 2017
  • Chart Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir (Leiyide) in Parts of China in 2017
  • Chart Prices of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir (Enganding) in Parts of China in 2017
  • Chart Forecast on Size of China's Entecavir Market, 2018-2022
Back to Top
전화 문의
이용안내
 
BCC Research